This is an update to NICE guideline NG217 (published April 2022 and previously updated January 2025).
We are reviewing recommendations 6.4.2 to 6.4.4 in section 6.4 on self-limited epilepsy with centrotemporal spikes. We are in the process of:
- reviewing the licensed status for treatments recommended for self-limited epilepsy with centrotemporal. spikes including the UK licencing approval of sultiame in January 2025.
- searching for any new evidence on treatments for self-limited epilepsy with centrotemporal spikes.
- we have appointed an expert working group to advise on any changes to recommendations.
- we will consult on any proposed changes.
This guidance will partially update the following:
- Status:
- In progress
- Decision:
- Awaiting decision
- Developed as:
- CG
- ID number:
- 1321
Email enquiries
If you have any queries please email Epilepsiescypadults@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 April 2026 | Committee list updated |
| 01 April 2026 | Declaration of interests |
| 01 April 2026 | Stakeholder list updated |
For further information on the guideline development process, please see how we develop NICE guidelines